Sequencing checkpoint inhibitor therapy in renal cell carcinoma

Mené dans 15 pays sur 522 patients atteints d'un carcinome à cellules rénales (durée médiane de suivi : 15,2 mois), cet essai randomisé de phase III évalue l'efficacité, du point de vue de la survie sans progression et de la survie globale, et la toxicité de l'ajout d'atézolizumab au cabozantinib après l'échec d'un traitement par inhibiteurs de points de contrôle immunitaire

Résumé en anglais

Initial therapy in patients with advanced renal cell carcinoma includes drugs that inhibit immune checkpoints, thereby blocking the negative regulators of an antitumour immune response. Currently, this therapy includes a combination of a PD-1 inhibitor and either a second checkpoint inhibitor, an antibody against CTLA4, or one of several small molecule inhibitors of the VEGF receptor. These PD-1-based combination therapies have improved clinical outcomes including overall survival. Although use of checkpoint inhibitor-based combination therapy has led to a subset of patients who have a durable response and disease control without the need for further systemic therapy, the majority of patients will progress and require additional treatment. (...)